Oncogenic alterations in eight genes (EGFR, KRAS, ALK, MET, ROS1, BRAF, RET, and NTRK) now have FDA- and European Medicines Agency–approved targeted therapies in NSCLC (8, 62). This evidence concerns the gene MET and non-small cell lung carcinoma.